(ACTU) Actuate Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •
ACTU: Cancer, Injection, Inhibitor
Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company specializing in the development of innovative cancer therapies. Its lead product candidate, Elraglusib Injection, is a glycogen synthase kinase-3 (GSK-3) inhibitor designed to target metastatic pancreatic ductal adenocarcinoma (PDAC). The company is also investigating Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. Formerly known as Apotheca Therapeutics, Inc., the company rebranded as Actuate Therapeutics, Inc. in October 2015. Headquartered in Fort Worth, Texas, Actuate Therapeutics was incorporated in 2015 and is focused on advancing its pipeline of precision oncology therapies.
The companys approach centers on leveraging its expertise in kinase inhibition to develop targeted therapies that address unmet medical needs in oncology. Elraglusib, its flagship candidate, has shown potential in preclinical and early clinical studies to inhibit tumor growth and enhance anti-tumor immunity. Actuate Therapeutics is committed to advancing Elraglusib through clinical development, with a focus on improving outcomes for patients with aggressive and hard-to-treat cancers.
Additional Sources for ACTU Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ACTU Stock Overview
Market Cap in USD | 153m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2024-08-13 |
ACTU Stock Ratings
Growth 5y | -21.2% |
Fundamental | -28.1% |
Dividend | 0.0% |
Rel. Strength Industry | -6.32 |
Analysts | - |
Fair Price Momentum | 6.44 USD |
Fair Price DCF | - |
ACTU Dividends
No Dividends PaidACTU Growth Ratios
Growth Correlation 3m | -34% |
Growth Correlation 12m | -2.2% |
Growth Correlation 5y | -2.2% |
CAGR 5y | -15.80% |
CAGR/Max DD 5y | -0.39 |
Sharpe Ratio 12m | -0.63 |
Alpha | -27.08 |
Beta | 1.09 |
Volatility | 75.34% |
Current Volume | 16.9k |
Average Volume 20d | 22.2k |
As of March 16, 2025, the stock is trading at USD 7.25 with a total of 16,939 shares traded.
Over the past week, the price has changed by +4.32%, over one month by -6.57%, over three months by -16.57% and over the past year by -15.80%.
Probably not. Based on ValueRay Fundamental Analyses, Actuate Therapeutics (NASDAQ:ACTU) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.14 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACTU as of March 2025 is 6.44. This means that ACTU is currently overvalued and has a potential downside of -11.17%.
Actuate Therapeutics has no consensus analysts rating.
According to ValueRays Forecast Model, ACTU Actuate Therapeutics will be worth about 7.2 in March 2026. The stock is currently trading at 7.25. This means that the stock has a potential downside of -0.14%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 7.2 | -0.1% |